Trade Moderna Inc. with LHFX

Moderna is a biotechnology company built around a single technology platform: messenger RNA (mRNA). The company's commercial revenue is currently dominated by Spikevax, the COVID-19 vaccine, which generated combined revenue above $18 billion in 2022, fell to around $6.7 billion in 2023, and roughly $3 billion in 2024 as government contracts wound down and the market shifted to private-sector commercial purchasing. The equity story is a transition from a single-product COVID vaccine company to a multi-product mRNA platform company. The pipeline contains mRNA-1345 (an RSV vaccine approved in 2024 as mRESVIA), mRNA-1083 (a combination COVID plus flu vaccine in late-stage development), seasonal flu vaccines, a CMV (cytomegalovirus) vaccine in Phase 3, individualised cancer vaccines (mRNA-4157 in combination with Merck's Keytruda for melanoma adjuvant therapy), and rare-disease programmes. The cancer vaccine programme is the most-watched single asset. The mRNA-4157 plus Keytruda combination showed a roughly 49% reduction in the risk of recurrence or death versus Keytruda alone in adjuvant melanoma in a Phase 2b trial, and Phase 3 trials are running in multiple tumour types. Positive Phase 3 readouts would be a substantial valuation catalyst; negative readouts have produced 20%+ single-day declines historically. Moderna had over $9 billion of cash and investments on the balance sheet at the end of 2023, which funds a multi-year R&D programme. Operating losses have widened as COVID revenue compressed and R&D spending stayed elevated. The company is targeting break-even operating profit by 2028 contingent on pipeline launches. At LHFX you trade MRNA as a CFD on the Moderna share price. You profit or lose based on price movement and can go long or short. You do not own the share, have no voting rights, and dividends are not currently paid. Maximum leverage on US single-stock CFDs is 1:20. Spreads are raw with a $3 per side commission.

Open an LHFX account, complete verification, and fund it from $10. Search MRNA in MetaTrader 5 or LHFX Trade. US cash hours apply: 14:30 to 21:00 UTC, Monday to Friday. CFDs pay a daily swap on positions held overnight. MRNA is one of the highest-volatility large-cap names in US healthcare. Average daily range has run around 3 to 5%, with single-day moves of 15 to 25% not uncommon around trial readouts, earnings guidance updates, and FDA decisions. Illustrative sizing at a $80 share price: a 25-share MRNA position is $2,000 of notional and requires $100 of margin at 1:20 leverage. A 5% adverse move (well within a normal day) costs $100, your entire margin. A 20% trial-readout adverse move costs $400. Round-trip commission on 25 shares is $6. MRNA reports earnings late February, early May, early August, and early November before the US market open. Implied moves on earnings have run 8 to 15%. Pipeline-readout days are scheduled around major medical conferences (ASCO in May, ESMO in September, AHA in November, ASH in December). Set a stop loss before entry. For a $2,000 account risking $40 per trade at a $1.60 stop distance, position size is 25 shares. Most experienced traders run effective leverage well below the 1:20 cap on MRNA.